Substituted Porphyrins
OwnerIrwin Fridovich, Ines Batinic-Haberle +2inventors
InventorsIrwin Fridovich, Ines Batinic-Haberle, James Crapo, Brian Day
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
Claims27
A compound of formula
- or pharmaceutically acceptable salt thereof,
- wherein
- each R is, independently, a C1-C8 alkyl group, and
- each P is, independently, an electron withdrawing group or hydrogen,
- wherein when each R is methyl and each P is hydrogen, said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.
A method of protecting cells from oxidant-induced toxicity comprising contacting said cells with a protective amount of a compound of formula
- or pharmaceutically acceptable salt thereof,
- wherein
- each R is, independently, a C1-C8 alkyl group, and
- each P is, independently, an electron withdrawing group or hydrogen.
A method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to said patient an effective amount of a compound of formula
- or pharmaceutically acceptable salt thereof,
- wherein
- each R is, independently, a C1-C8 alkyl group, and
- each P is, independently, an electron withdrawing group or hydrogen.
A method of treating a pathological condition of a patient resulting from degradation of NO. or a biologically active form thereof, comprising administering to said patient an effective amount of a compound of formula
- or pharmaceutically acceptable salt thereof,
- wherein
- each R is, independently, a C1-C8 alkyl group, and
- each P is, independently, an electron withdrawing group or hydrogen.
A method of treating a patient for inflammatory lung disease comprising administering to said patient an effective amount of a compound of formula
- or pharmaceutically acceptable salt thereof,
- wherein
- each R is, independently, a C1-C8 alkyl group, and
- each P is, independently, an electron withdrawing group or hydrogen.
Dependencies are inferred from the claim text.